Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Weak PR

Re: Weak PR

posted on Mar 08, 2007 07:59AM

In seeing the ammended SB-2 there have only been a few million of those previously restricted shares changed. I didn't go back to see if it was only a decrease in the offering or who did sell some.

My thought is that ....we didn't take advantage of the agreement with S/L for the 10mil.(2mil per month) and possibly another 10 mil. warrant buyback, so it looks like they have changed the plan...letting S/L go to the open market.

Problem that no one mentions when they get excited about getting rid of the warrants is that there is dilution for every share converted. And are these shares going to stronger hands or who. Was it 30 some from S/L and 7 mil. unregistered possible from the SB-2? With only 10mil. bought back, we are diluting.

A good question for ASM may be what number of shares would management like to get to. Going to a new exchange would require enough liqiudity but not too much as we reach a max. market cap very quickly. Of course a major monitary win in Texas would certainly boost market cap ability. Still hope for a holdout being this far in.

Share
New Message
Please login to post a reply